IDEXX Laboratories’ Q2 Earnings Top Estimates, Analyst Maintain Outperform Citing Resilient Animal Health Market

IDEXX Laboratories Inc (NASDAQ:IDXX) reported Q2 FY23 sales of $943.63 million, beating the consensus of $927.84 million. Adjusted EPS was $2.67 versus $1.56 a year ago.

The sales increased by 10% reported and 10% organic, driven by Companion Animal Group (CAG) growth of 11% and organic and Water revenue growth of 10% reported and 9% organic.